Artículos de revistas sobre el tema "Immune check point inhibitor"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Immune check point inhibitor".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Jaswani, Tamika S., Meeta Desai, Douglas Grider y Jonathan M. Bern. "Immune Check Point Inhibitor-induced Colitis". American Journal of Gastroenterology 112 (octubre de 2017): S858—S860. http://dx.doi.org/10.14309/00000434-201710001-01575.
Texto completoBobart, Shane A., Itunu Owoyemi, Joseph Grande, Nelson Leung y Sandra M. Herrmann. "Immune Check Point Inhibitor–Associated Endothelialitis". Kidney International Reports 5, n.º 8 (agosto de 2020): 1371–74. http://dx.doi.org/10.1016/j.ekir.2020.05.027.
Texto completoAshour, Tarek, Georges Nakhoul, Pradnya Patil, Pauline Funchain y Leal Herlitz. "Immune Check Point Inhibitor–Associated Glomerulonephritis". Kidney International Reports 4, n.º 2 (febrero de 2019): 355–59. http://dx.doi.org/10.1016/j.ekir.2018.10.017.
Texto completoKumar, Aswini, Maximilian Lee y Talhat Azemi. "IMMUNE CHECK POINT INHIBITOR MYOCARDITIS MIMICKING ACS". Journal of the American College of Cardiology 73, n.º 9 (marzo de 2019): 2681. http://dx.doi.org/10.1016/s0735-1097(19)33287-5.
Texto completoNilajgi, Shalini, Nicholas Kasmeridis y Kichendasse Ganessan. "A Case Of Immune Check Point Inhibitor - Induced Hypophysitis". Journal of the Endocrine Society 5, Supplement_1 (1 de mayo de 2021): A560. http://dx.doi.org/10.1210/jendso/bvab048.1142.
Texto completoSuchý, David. "Immune-related adverse events associated with immune check-point inhibitors". Klinická farmakologie a farmacie 33, n.º 3 (28 de octubre de 2019): 20–24. http://dx.doi.org/10.36290/far.2019.019.
Texto completoMarthey, Lysiane, Raef Abdallah, Christophe Bellanger, Clément Bresteau, Antoine Meyer, Aurélien Amiot y Franck Carbonnel. "Immune check-point inhibitors related enterocolitis". Hépato-Gastro & Oncologie Digestive 30, n.º 8 (octubre de 2023): 826–32. http://dx.doi.org/10.1684/hpg.2023.2641.
Texto completoJohncilla, Melanie, Shilpa Grover, Xuchen Zhang, Dhanpat Jain y Amitabh Srivastava. "Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis". Histopathology 76, n.º 4 (18 de febrero de 2020): 531–39. http://dx.doi.org/10.1111/his.14029.
Texto completoKim, Jin Young, Chi Heum Cho y Hong Suk Song. "Targeted therapy of ovarian cancer including immune check point inhibitor". Korean Journal of Internal Medicine 32, n.º 5 (1 de septiembre de 2017): 798–804. http://dx.doi.org/10.3904/kjim.2017.008.
Texto completoVergne-Santiago, Norma, Ernesto Jos E. Sola Sanchez y Michelle Marie Mangual Garcia. "Immune Check Point Inhibitors Triggering Non Autoimmune Polyendocrinopathy". Journal of the Endocrine Society 5, Supplement_1 (1 de mayo de 2021): A136—A137. http://dx.doi.org/10.1210/jendso/bvab048.275.
Texto completoKorotaeva, A. A., N. V. Apanovich, E. A. Braga, V. B. Matveev y A. V. Karpukhin. "Current advances in kidney cancer immunotherapy". Cancer Urology 15, n.º 4 (16 de enero de 2020): 30–38. http://dx.doi.org/10.17650/1726-9776-2019-15-4-30-38.
Texto completoMaster, Samip R., Arelis Robinson, Glenn Morris Mills y Richard P. Mansour. "Cardiovascular complications of immune checkpoint inhibitor therapy." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): 2568. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2568.
Texto completoDurno, Carol A., Melyssa Aronson, Melissa Edwards, Simon Ling, Valérie Larouche, Annika Bronsema, Michael Osborn et al. "Immune Check Point Inhibitor Treatment for Young Patients with Hypermutant Cancers". Gastroenterology 152, n.º 5 (abril de 2017): S141. http://dx.doi.org/10.1016/s0016-5085(17)30801-6.
Texto completoAlbert, Stewart, Gouyu Ling, Srikanth Nadella y Aparna Yeggalam. "ODP170 Check Point Inhibitor Associated Multi-Endocrine Dysfunction Presenting With Euglycemic Ketoacidosis". Journal of the Endocrine Society 6, Supplement_1 (1 de noviembre de 2022): A71—A72. http://dx.doi.org/10.1210/jendso/bvac150.148.
Texto completoKapoor, Vidit y Olivier Rixe. "Toxicity of PD-1/CTLA-4 inhibitor immunotherapy among elderly patients." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): e14139-e14139. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14139.
Texto completoSchmidinger, Manuela, Irene Resch, Harun Fajkovic, Mesut Remzi, Shahrokh F. Shariat y Jens Bedke. "Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?" Current Opinion in Urology 31, n.º 3 (11 de marzo de 2021): 270–75. http://dx.doi.org/10.1097/mou.0000000000000874.
Texto completoThomas, Richard, Bibin Sebastian, Tom George, Noor Fatima Majeed, Temilola Akinola, Shawn L. Laferriere y Marta Braschi-Amirfarzan. "A review of the imaging manifestations of immune check point inhibitor toxicities". Clinical Imaging 64 (agosto de 2020): 70–79. http://dx.doi.org/10.1016/j.clinimag.2020.04.007.
Texto completoMbaraonye, Uchenne, Lily Romero Karam, Cindy Nguyen, Deepa Gotur y Simon Yau. "IMMUNE CHECK POINT INHIBITOR-INDUCED ORGANIZING PNEUMONIA IN A LUNG TRANSPLANT PATIENT". Chest 158, n.º 4 (octubre de 2020): A1135—A1136. http://dx.doi.org/10.1016/j.chest.2020.08.1038.
Texto completoArcari, Luca, Giacomo Tini, Giovanni Camastra, Federica Ciolina, Domenico De Santis, Domitilla Russo, Damiano Caruso, Massimiliano Danti y Luca Cacciotti. "Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review". Journal of Imaging 8, n.º 4 (5 de abril de 2022): 99. http://dx.doi.org/10.3390/jimaging8040099.
Texto completoMathew Thomas, Vinay, Poorva Bindal, Swetha Ann Alexander y Kymberly McDonald. "Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor". Journal of Oncology Pharmacy Practice 26, n.º 2 (25 de marzo de 2019): 459–61. http://dx.doi.org/10.1177/1078155219837342.
Texto completoDas, Undurti N. "Bioactive lipids as modulators of immune check point inhibitors". Medical Hypotheses 135 (febrero de 2020): 109473. http://dx.doi.org/10.1016/j.mehy.2019.109473.
Texto completoLleo, Ana, Lorenza Rimassa y Massimo Colombo. "Hepatotoxicity of immune check point inhibitors: Approach and management". Digestive and Liver Disease 51, n.º 8 (agosto de 2019): 1074–78. http://dx.doi.org/10.1016/j.dld.2019.06.017.
Texto completoKiyota, Naomi. "Immune check point inhibitors for head and neck cancer". Toukeibu Gan 44, n.º 4 (2018): 336–41. http://dx.doi.org/10.5981/jjhnc.44.336.
Texto completoSørensen, A. S., M. Nørgaard Andersen, K. Juul-Madsen, C. Skejø, H. Schmidt, T. Vorup-Jensen y T. W. Kragstrup. "OP0130 IN VITRO CHARACTERIZATION OF INFLAMMATORY ARTHRITIS ASSOCIATED WITH IMMUNE CHECK POINT INHIBITION". Annals of the Rheumatic Diseases 79, Suppl 1 (junio de 2020): 85.1–85. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1356.
Texto completoMudunov, A. M., A. V. Ignatova, A. S. Morozova, S. O. Podvyaznikov y Yu V. Alymov. "Combination of concurrent targeted and immune-therapy with nivolumab and cetuximab: new perspectives for squamous cell carcinoma treatment". Head and Neck Tumors (HNT) 10, n.º 3 (16 de noviembre de 2020): 111–17. http://dx.doi.org/10.17650/2222-1468-2020-10-3-111-117.
Texto completoElkayam, Natalie y Shaurya Sharma. "Dual checkpoint inhibitor induced autoimmune encephalitis". Archive of Oncology 25, n.º 2 (2019): 22–24. http://dx.doi.org/10.2298/aoo181230003e.
Texto completoTaylor, C., M. Reno y D. Sharma. "Secondary sclerosing cholangitis: a lesser known side effect of pembrolizumab therapy". American Journal of Clinical Pathology 156, Supplement_1 (1 de octubre de 2021): S123—S124. http://dx.doi.org/10.1093/ajcp/aqab191.263.
Texto completoIbraheim, Hajir, Esperanza Perucha y Nick Powell. "Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors". Rheumatology 58, Supplement_7 (1 de diciembre de 2019): vii17—vii28. http://dx.doi.org/10.1093/rheumatology/kez465.
Texto completoDrommi, Fabiana, Alessia Calabrò, Grazia Vento, Gaetana Pezzino, Riccardo Cavaliere, Fausto Omero, Paola Muscolino et al. "Crosstalk between ILC3s and Microbiota: Implications for Colon Cancer Development and Treatment with Immune Check Point Inhibitors". Cancers 15, n.º 11 (24 de mayo de 2023): 2893. http://dx.doi.org/10.3390/cancers15112893.
Texto completoKeyes, Erin, Muhammad B. Hammami y Kendall R. Beck. "2555 Immune Check Point Inhibitor Enteritis: A Case of Severe Duodenitis From Nivolumab Therapy". American Journal of Gastroenterology 114, n.º 1 (octubre de 2019): S1405. http://dx.doi.org/10.14309/01.ajg.0000599752.28233.77.
Texto completoSanchez, Carlos A. Vergara, Rashid Alhusain, Jordan Christopher Ray y Julio Perez-Downes. "A CASE OF IMMUNE CHECK POINT INHIBITOR MEDIATED MYOPERICARDITIS: MANAGING A RARE ADVERSE REACTION". Journal of the American College of Cardiology 83, n.º 13 (abril de 2024): 3204. http://dx.doi.org/10.1016/s0735-1097(24)05194-5.
Texto completoAlbarel, Frédérique, Frédéric Castinetti y Thierry Brue. "MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis". European Journal of Endocrinology 181, n.º 3 (septiembre de 2019): R107—R118. http://dx.doi.org/10.1530/eje-19-0169.
Texto completoSoares, Adriana, Rafael Carmo, Catarina Rodrigues, Inês Teles Grilo y Enrique Grande. "Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer". Bladder Cancer 6, n.º 1 (28 de marzo de 2020): 1–8. http://dx.doi.org/10.3233/blc-190260.
Texto completoOrloff, Marlana, Ryan Weight, Matias E. Valsecchi y Takami Sato. "Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?" Reviews on Recent Clinical Trials 11, n.º 2 (1 de mayo de 2016): 81–86. http://dx.doi.org/10.2174/1574887111666160330120712.
Texto completoKiyota, Naomi. "Current status of immune check point inhibitors for solid malignancy". Annals of Oncology 27 (noviembre de 2016): vii5. http://dx.doi.org/10.1093/annonc/mdw453.
Texto completoStruble, Roger, Vikas Koppurapu, Derek Hupp, Yana Zemkova, Andrei Schwartz, Jeff Wilson y Charles Rappaport. "YIELD OF BAL IN PATIENTS RECEIVING IMMUNE CHECK POINT INHIBITORS". Chest 158, n.º 4 (octubre de 2020): A1935. http://dx.doi.org/10.1016/j.chest.2020.08.1675.
Texto completoGupta, Tarana y Nikhil Sai Jarpula. "Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status". World Journal of Hepatology 16, n.º 3 (27 de marzo de 2024): 353–65. http://dx.doi.org/10.4254/wjh.v16.i3.353.
Texto completoM. Guirgis, Helmy. "The Impact of The Immune Check Point Duration of use on Cost in Lung Cancer". Pharmaceutics and Pharmacology Research 5, n.º 6 (30 de mayo de 2022): 01–05. http://dx.doi.org/10.31579/2693-7247/086.
Texto completoChintalacheruvu, Lakshmi Manogna, Kushal Naha, Vamsi Krishna Chilluru y Donald C. Doll. "Review of neurological side effects associated with checkpoint inhibitor therapy in cancer patients." Journal of Clinical Oncology 38, n.º 5_suppl (10 de febrero de 2020): 72. http://dx.doi.org/10.1200/jco.2020.38.5_suppl.72.
Texto completokazuhiro, S., K. Sugiyama, K. Nozawa, Y. Funahashi, Y. Kogure, C. Kitagawa, S. Ichihara, R. Nishimura, T. Kubota y H. Saka. "Single-institute, retrospective study of metastatic uveal melanoma in the immune check point inhibitor era". Annals of Oncology 29 (noviembre de 2018): ix106. http://dx.doi.org/10.1093/annonc/mdy439.005.
Texto completoMalkova, A. M., R. V. Orlova, N. V. Zhukova, A. R. Gubal y V. V. Sharoiko. "Analysis of possible markers of effective antitumor cellular immune response before starting therapy with immune check-point inhibitors". Siberian journal of oncology 21, n.º 2 (8 de mayo de 2022): 109–17. http://dx.doi.org/10.21294/1814-4861-2022-21-2-109-117.
Texto completoRevathi, Duraisamy, Ganapathy Dhanraj y V. Ashok. "Immune check point inhibitors: A promising therapeutic approach in oral cancer". Oral Oncology 132 (septiembre de 2022): 105977. http://dx.doi.org/10.1016/j.oraloncology.2022.105977.
Texto completoKhamnueva, L. Yu Khamnueva, K. A. Sergeeva Sergeeva, L. S. Andreeva Andreeva y A. V. Davydova Davydova. "Endocrinopathies induced by immune check point inhibitors. Optimal patient management tactics". Pharmateca 12_2020 (23 de noviembre de 2020): 8–13. http://dx.doi.org/10.18565/pharmateca.2020.12.8-13.
Texto completoStringer, Bryan F., Nikhila Kethireddy, Alain Rizkallah y Konstadina Darsaklis. "MYOCARDITIS SECONDARY TO IMMUNE CHECK-POINT INHIBITORS: DIFFICULTIES IN ARRHYTHMIA MANAGEMENT". Journal of the American College of Cardiology 75, n.º 11 (marzo de 2020): 2694. http://dx.doi.org/10.1016/s0735-1097(20)33321-0.
Texto completoMuhailan, Mohamad y Ghassan Al-Shbool. "Pseudo-Wellens’ Syndrome Temporally Associated With Immune Check Point Inhibitors Use". American Journal of the Medical Sciences 359, n.º 1 (enero de 2020): e1-e2. http://dx.doi.org/10.1016/j.amjms.2019.07.006.
Texto completoKim, Hyunseok, Soyeon Ahn, Hyungjin Kwon, Hsuan-Ju Chen, Inwon Park, Pilhan Kim y Akyildiz Kubra. "Abstract 2397: An advanced approach technique for tracking point between immune check point inhibitor and cancer cell mechanism in immune response motility by infiltration a breast cancer cell". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 2397. http://dx.doi.org/10.1158/1538-7445.am2023-2397.
Texto completoRoy, Arya Mariam y Saby George. "Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena". Cancer Drug Resistance 6, n.º 3 (20 de septiembre de 2023): 642–55. http://dx.doi.org/10.20517/cdr.2023.47.
Texto completoFurnish, Robin, Heather Bear, Xin Wei y Timothy Phoenix. "MODL-29. EVALUATING TUMOR-IMMUNE INTERACTIONS IN MOUSE MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA". Neuro-Oncology 22, Supplement_3 (1 de diciembre de 2020): iii417. http://dx.doi.org/10.1093/neuonc/noaa222.602.
Texto completoDe Felice, Francesca, Daniela Musio y Vincenzo Tombolini. "Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment". Journal of Personalized Medicine 11, n.º 5 (10 de mayo de 2021): 393. http://dx.doi.org/10.3390/jpm11050393.
Texto completoKikuchi, Yoshihiro, Hiroko Kouta, Takayoshi Asakawa, Miyuki Horikoshi, Tomoyuki Yoshikawa, Masashi Takano y Kenichi Furuya. "Roles of an immune-check point inhibitor (nivolumab) in heavily pretreated and platinum-resistant gynecologic cancers." Journal of Clinical Oncology 36, n.º 15_suppl (20 de mayo de 2018): e17562-e17562. http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e17562.
Texto completo